Evolus Inc (EOLS) Actualités

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

Evolus dermal filler, Evolysse™ Lift, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary...

Form 4 - Statement of changes in beneficial ownership of securities

Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit

David Moatazedi, President and Chief Executive Officer of Evolus, is first medical aesthetics leader to be a speaker at WWD Beauty CEO Summit...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the...

Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Evolus Reports First Quarter 2024 Results and Provides Business Update

Q1 2024 Net Revenue of $59.3 Million, Up 42% from Q1 2023 Non-GAAP Loss from Operations of $0.9 Million, on Track to Non-GAAP Profitability1 in...

Evolus to Report First Quarter Financial Results on May 7, 2024

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced...